In cancer treatment, RAS-selective lethal small molecule 3 (RSL3), a ferroptosis-specific inducer, demonstrates antitumor efficacy by inducing ferroptosis in colorectal cancer via GPX4 inactivation and ROS production [9]. Here, GPX4 is linked to cancer.